ReviewCancer reports (Hoboken, N.J.)2026
The Role of Chemopreventive Agents in the Management of Oral Potentially Malignant Disorders and Oral Cancer: A Narrative Review.
Review in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) is a common and aggressive cancer sometimes subsequent to oral potentially malignant disorders (OPMDs). Notwithstanding progress in surgical, radiotherapeutic, and chemotherapeutic interventions, survival rates for OSCC continue to be inadequate and are associated with significant functional impairment, underscoring the necessity for preventive and interceptive therapeutic approaches. Chemoprevention has emerged as a viable strategy to inhibit, postpone, or reverse oral carcinogenesis by targeting the molecular and cellular processes implicated in malignant transformation. RECENT
findingsThis review synthesizes current evidence on chemopreventive agents investigated in OPMDs and OSCC. Relevant literature was analyzed focusing on natural compounds, synthetic drugs, and targeted biological therapies, as well as emerging delivery approaches. Significant emphasis is placed on bioactive phytochemicals such as retinoids, carotenoids (β-carotene and lycopene), curcumin, resveratrol, black raspberries, and vitamin E, alongside synthetic agents including cyclooxygenase-2 inhibitors and epidermal growth factor receptor (EGFR)-targeted therapies. These drugs demonstrate chemopreventive effects via modulating oxidative stress, inflammation, cell cycle regulation, apoptosis, angiogenesis, epithelial-mesenchymal transition, and immune evasion in the tumor microenvironment. Clinical and experimental investigations examined in this review reveal inconsistent, although promising results, including the regression of dysplasia, decreased rates of malignant transformation, and enhanced molecular risk profiles in OPMDs. Nonetheless, obstacles persist about long-term effectiveness, ideal dose, toxicity, and patient adherence.
conclusionChemopreventive medicines, especially when utilised in combination and through sophisticated delivery systems, signify a prospective adjunct or alternative approach in the care of OPMDs and OSCC, with the capacity to diminish disease burden and enhance patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.